ISRG vs BSX: Which Medical Device Stock Has More Room to Run?
In a healthcare landscape increasingly shaped by technology, two names that stand out for their innovation and long-term potential are Intuitive Surgical ISRG and Boston Scientific BSX. Both companies are at the forefront of minimally invasive procedures — Intuitive as the undisputed leader in robotic-assisted surgery, and Boston Scientific as a powerhouse in interventional medical devices.
With growing demand for advanced surgical solutions and aging global populations driving healthcare needs, investors are eyeing these med-tech giants as attractive long-term plays. But, which stock offers more compelling upside right now? Let's break down the fundamentals, growth trajectories, and market positions of ISRG and BSX to find out which one deserves a place in your portfolio.
ISRG & BSX: Price Performance
Intuitive Surgical represents a high-growth, high-premium pure play on robotic-assisted surgery. Its exceptional performance and growth provide compelling upside, but investors must accept margin compression and valuation risk in the short-to-medium term. Boston Scientific offers broader exposure to medical device innovation, with reliable growth driven by cardiovascular and interventional segments. It trades at a more moderate valuation and may appeal to investors seeking growth with less volatility.
The year-to-date price performance of Intuitive Surgical has not been impressive, likely due to tariff concerns and rising competition from Chinese robotic device makers. However, BSX has outperformed ISRG likely due to its diversified business as well as strong U.S. demand. Shares of ISRG have lost 1.9% year to date, while those of BSX have gained 13.9%.
Market Position & Core Offerings
Intuitive Surgical dominates the surgical robotics niche with its flagship da???Vinci system, which continues to gain traction globally — 367 new units placed in the first quarter of 2025 alone, leading to a 17% year-over-year increase in procedures. Boston Scientific, by contrast, operates across a broader landscape of interventional medical devices, from cardiovascular to neuromodulation. Its success with Farapulse pulsed field ablation and strong cardiovascular sales (+26% in first-quarter 2025) highlight its diversified growth drivers.
Growth & Performance
ISRG delivered robust first-quarter 2025 results: revenues grew 19% to $2.25 billion, adjusted net income rose 22% to $767.5 million, and adjusted EPS grew 21% to $1.81. Its projected procedure growth remains strong at 15-17% for the year, though margins may be pressured by tariffs.
BSX also posted solid first-quarter 2025 earnings, with adjusted EPS of $0.75 and sales worth $4.66 billion, both beating expectations on the back of cardiovascular and medical-surgical divisions. For the second quarter of 2025, revenues are expected to grow by double digits, driven by PFA and other interventions.
Estimates Comparison for ISRG & BSX
The Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 6.8%, respectively. EPS estimates for 2025 and 2026 have trended southward over the past 60 days.
ISRG Estimate Movement
The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. Moreover, EPS estimates for 2025 and 2026 have improved over the past 60 days.
BSX Estimate Movement
Cash & Cash Flow
Intuitive Surgical maintains an exceptionally strong balance sheet, with $4.51 billion in cash and no debt as of the first quarter of 2025. The company generated free cash flow of around $465 million and operating cash flow of $582 million, driven by continued growth in da Vinci system procedures and high-margin recurring revenues from instruments and accessories.
Boston Scientific, operates with a more leveraged profile. The company reported $725 million in cash and $11.31 billion in total debt, with a debt-to-equity ratio of nearly 50%. Despite this, BSX maintains strong cash generation, posting $541 million in operating cash flow and $354 million in free cash flow for the first quarter of 2025 alone. Its diversified product base, especially in cardiovascular and electrophysiology, supports ongoing growth and debt service.
Risks & Operational Challenges
ISRG is exposed to geopolitical and trade-related tariff risks — especially a 125% tariff on Chinese exports — which have led to margin revisions for 2025. Mitigation efforts include supply-chain adjustments and pricing flexibility. BSX contends with regulatory and legal exposures (notably from past medical-device recalls and mesh product lawsuits), but its diversified supply chain and global footprint help buffer macroeconomic pressures.
ISRG or BSX: Which Is a Better Bet?
For investors focused on explosive, category-leading growth in surgical robotics, ISRG may still be the superior choice. But those who prefer balanced exposure across med-tech segments with a steadier valuation profile might consider BSX as a more diversified, resilient option.
Intuitive Surgical stands out for its pristine balance sheet, zero debt, and strong free cash flow, making it an appealing choice for investors prioritizing financial stability and growth. Boston Scientific's leveraged balance sheet is offset by a diversified product base and solid, consistent cash generation, positioning it as a resilient and innovative med-tech player for investors comfortable with moderate financial risk.
Both companies currently carry a Zacks Rank #3 (Hold). However, if we go by the Zacks Style Score, BSX seems to be a better bet compared to ISRG. While ISRG has a Zacks Style Score of 'D', BSX's score is 'C', reflecting better growth potential.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Should You Buy Micron Stock Before June 25?
Micron (NASDAQ: MU) is scheduled to report quarterly financial results after the stock markets close on June 25, 2025. That has investors wondering if they should buy the semiconductor stock before the company announces its earnings results. *Stock prices used were the afternoon prices of June 18, 2025. The video was published on June 20, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Should you invest $1,000 in Micron Technology right now? Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of June 9, 2025 Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Globe and Mail
an hour ago
- Globe and Mail
Advantages of Social Security Privatization, According to Experts
If you want to get people worked up, ask a small group of friends what they think of Social Security privatization. Privatization refers to the idea of shifting the management and funding of retirement from the government to individuals. In other words, rather than paying Social Security taxes as part of FICA, you would keep the money and invest for retirement on your own. Experts have dramatically different opinions on privatization, with some fearing that it will lead to more people entering retirement with little to no financial resources. Those arguing in favor of privatizing the program take a completely different view. Here's how they believe the change would benefit the average American worker. Higher returns Imagine that a portion of your Social Security taxes were invested in a personal account rather than used to fund current retirees' benefits. You could invest in stocks and bonds to your heart's content. In fact, you could invest in any vehicle you believe will provide a strong return. Compounding interest One of the beauties of investing is the way compound interest can significantly increase your retirement savings over time. As long as you begin investing early and are consistent, proponents of privatization believe you're in a position to build up more money than you could ever collect through Social Security payments. More flexibility Proponents believe that Americans will appreciate the ability to invest their retirement savings where they want. Rather than paying it into a program supporting current retirees, they can choose where their money will go. However, the open question becomes: What happens to the millions of current retirees when workers stop paying into the system? Focus on personal responsibility Read any message board, and you're likely to find plenty of people with an opinion about Social Security privatization. It's been a hot-button topic since President George W. Bush first suggested it in his 1978 Congressional race, then pushed for it again following his successful 2004 presidential campaign. Since that time, the subject has been supported by a rotating cast of politicians, who claim it will put the responsibility for saving on individuals rather than allowing them to depend on the government to provide a safety net. While this reasoning overlooks the fact that Americans spend decades contributing to the system and Social Security has never been a public assistance program, it does appeal to the "pull yourself up by your bootstraps" crowd. Greater financial literacy Proponents believe that pushing Americans to invest on their own means greater financial literacy among the masses. It's also believed that it will foster a culture of savings and investment. While this may be true for some, it's fair to imagine that wealthier Americans can afford to pay financial planners to help them make the most of their investments, while workers living paycheck to paycheck may have trouble saving the funds at all. It's likely that most people would like to save for retirement, but not everyone can afford to do so. The good news is that plenty of people are actively involved in seeking a solution to potential Social Security shortages. It may turn out that some form of Social Security privatization -- such as a hybrid system that allows you to continue paying into the current system while setting aside some money to make your own investments -- will be the answer. Or, it may be something entirely different. While proponents of Social Security privatization offer numerous potential advantages, it's yet to be seen if anyone will come up with a better solution. The $23,760 Social Security bonus most retirees completely overlook If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. One easy trick could pay you as much as $23,760 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after. Join Stock Advisor to learn more about these strategies.
Globe and Mail
an hour ago
- Globe and Mail
Tesla Stock (TSLA) Buying Opportunity if Robotaxis are Another ‘Musk Mirage'
Tesla's (TSLA) much-anticipated robotaxi launch later this week is a 'pivotal' moment for the under-fire business, with any failure likely to severely hit its valuation and long-term revenue hopes. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Another 'Musk Mirage,' however, could create a buying opportunity for investors. Grand Illusion The warning from Saxo's global head of investment strategy Jacob Falkencrone comes ahead of Tesla's robotaxi launch on June 22 in Austin, Texas. 'It is a concept Elon Musk [Tesla chief executive] has relentlessly hyped as the cornerstone of Tesla's next trillion-dollar chapter,' he said. 'Investors now hold their breath. Will this launch deliver transformative change or prove yet another of Musk's grand illusions?' The robotaxi pilot will deploy roughly ten autonomous Model Y vehicles powered by Tesla's Full Self-Driving (FSD) software. Falkencrone said that while this is being marketed as fully autonomous, these robotaxis will initially operate within strict geo-fenced areas under remote human supervision—a controlled test environment 'reflecting cautious regulatory navigation rather than bold innovation.' Mobility Revolution Analysts estimate robotaxis could cut travel costs by up to 70%, revolutionizing urban transport and shifting Tesla from a carmaker to a global mobility giant. 'Robotaxis could redefine Tesla's revenue model, potentially surpassing its car business,' Falkencrone said. However, he said skepticism remains warranted given intense scrutiny from regulators and public safety advocates. Indeed, Democratic legislators in Texas recently publicly urged Tesla to postpone its rollout until new safety laws take effect on September 1. The National Highway Traffic Safety Administration (NHTSA) is also actively investigating Tesla's autonomous driving systems following multiple incidents. 'Historically, Tesla's stock follows a predictable pattern around product launches—rising sharply on anticipation and falling on reality,' Falkencrone said. 'The payoff potential is enormous, but so are the pitfalls. Positive early signs could signal a powerful, investable opportunity. Conversely, setbacks could create short-term buying opportunities amid volatility.' Is TSLA a Good Stock to Buy Now? On TipRanks, TSLA has a Hold consensus rating based on 14 Buy, 12 Hold and 9 Sell ratings. Its highest price target is $500. TSLA stock's consensus price target is $286.14 implying an 11.15% downside. See more TSLA analyst ratings
